Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

Diabetes Care
Swneke D BaileyDREAM investigators

Abstract

Thiazolidinediones are used to treat type 2 diabetes. Their use has been associated with peripheral edema and congestive heart failure-outcomes that may have a genetic etiology. We genotyped 4,197 participants of the multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial with a 50k single nucleotide polymorphisms (SNP) array, which captures ∼2000 cardiovascular, inflammatory, and metabolic genes. We tested 32,088 SNPs for an association with edema among Europeans who received rosiglitazone (n = 965). One SNP, rs6123045, in NFATC2 was significantly associated with edema (odds ratio 1.89 [95% CI 1.47-2.42]; P = 5.32 × 10(-7), corrected P = 0.017). Homozygous individuals had the highest edema rate (hazard ratio 2.89, P = 4.22 × 10(-4)) when compared with individuals homozygous for the protective allele, with heterozygous individuals having an intermediate risk. The interaction between the SNP and rosiglitazone for edema was significant (P = 7.68 × 10(-3)). Six SNPs in NFATC2 were significant in both Europeans and Latin Americans (P < 0.05). Genetic variation at the NFATC2 locus contributes to edema among individuals who receive rosiglitazone.

References

May 3, 2001·The New England Journal of Medicine·J TuomilehtoUNKNOWN Finnish Diabetes Prevention Study Group
May 2, 2002·Cell·Gerald R Crabtree, Eric N Olson
Dec 3, 2002·The American Journal of Medicine·Shaun Cho, J Edwin Atwood
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Oct 24, 2006·Diabetes Research and Clinical Practice·Helen D BerlieLinda A Jaber
May 15, 2008·The Journal of Biological Chemistry·Meriem BourajjajLeon J De Windt
Nov 11, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Gualberto RuañoSteven Hanks

❮ Previous
Next ❯

Citations

Jan 20, 2011·Human Genetics·Lei SunShelley B Bull
Jul 5, 2012·Translational Psychiatry·D E AdkinsE J C G van den Oord
Feb 9, 2012·Gene·Andrea Brancaccio
Apr 12, 2016·Nature Reviews. Endocrinology·Kaixin ZhouEwan R Pearson
May 20, 2015·Blood·Christian A FernandezMary V Relling
Mar 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Sunil K KotaKirtikumar D Modi
May 18, 2016·Current Heart Failure Reports·Ersilia M DeFilippis, Michael M Givertz
Oct 17, 2015·Journal of the American Society of Nephrology : JASN·Xiaoli ZhouZhongjie Sun
Sep 7, 2016·Pharmacology & Therapeutics·Ilia GoltsmanZaid Abassi
Feb 21, 2018·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Michelle ThundersPeter Stockwell
Jun 28, 2017·Pharmacotherapy·Nina Elk, Otito F Iwuchukwu
Jan 10, 2019·BMC Evolutionary Biology·Langyu Gu, Canwei Xia
Jul 2, 2021·Frontiers in Genetics·Assefa M BayeAdem Y Dawed
Jul 10, 2021·Frontiers in Genetics·Aamir RainaRais A Ganai

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear translocation

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.